According to CNBC-TV18's research analyst Ekta Batra it's SPARC which has emerged as the winner from this deal between Sun Pharma and Merck. They are targeting a portfolio of around 12 drugs in around 100 countries but the focus is expected to be the top 10 countries which are expected to contribute around 80% of revenues.
first published: Apr 13, 2011 02:37 pm
A collection of the most-viewed Moneycontrol videos.
Iran–US Conflict: Will India’s Fiscal Deficit, Rupee & Markets Take a Hit? | Centre Point
Oil Shock: India’s Oil Security at Stake | Is an LNG Shock Coming for India? | Commodities with MC
Monday Mayhem in markets| Brent surges 18%, Global markets slide 2-8% | Nifty Set for Gap Down Open
PM Modi Speech: PM Modi Accuses TMC of Insulting President Murmu and Constitution
